Medicine: Non-amines can significantly reduce the risk of prostate cancer.

Prostate cancer prevention trials have shown that non-anarenaline has a protective effect on prostate cancer, but it has also shown that non-anaestamine can increase the risk of high levels of prostate cancer.
studies have investigated the relationship between phosphonamide and prostate cancer, but the results are not consistent.
study, we conducted a systematic literature review and meta-analysis to assess the relationship between phosphonamide and prostate cancer.
used pubMed, EMBASE, Science Direct/Elsevier, MEDLINE, CNKI, and Cochrane libraries to conduct systematic literature searches until October 2018 to determine studies involving the relationship between finamphetamine and prostate cancer.
use Review Manager and Stata software for Meta analysis.
in random or fixed-effect models, the combined OR is determined with a 95% confidence interval (95% CI).
results, the study identified a total of eight studies, including 54,335 patients who used non-amine and 9,197 patients who were controlled for a placebo.
results showed a significant correlation between the use of phosphonamide and prostate cancer, with a combined OR value of 0.70 ( 0.51, 0.96 ) .
there was also a significant correlation between the use of phosphonamine and high prostate cancer, with a combined OR value of 2.10 .
, the results of this study showed that non-anaeramine significantly reduced the risk of prostate cancer, but the level of malignant prostate cancer increased.
a larger sample size study is needed to better understand the correlation between the use of non-amines and prostate cancer.
.